tirzepatide for perimenopause leads to significant weight loss in women Perimenopause And GLP-1 Weight Loss

Wegovy and Ozempic are registered trademarks of Novo Nordisk

doi:10.1016/S0026-0495(97)90154-2

Ongoing monitoring typically involves monthly or quarterly check-ins during dose titration, regular assessment of weight loss progress and tolerability, periodic lab work to monitor metabolic parameters, and screening for potential complications

Blood pressure in early autosomal dominant polycystic kidney disease

Researchers looked at past data to compare outcomes among people treated with either with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist), or GLP-1 RA (glucagon-like peptide 1 receptor agonist treatment)

Regular blood work every 3-6 months helps catch deficiencies early